Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.40 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12361500 | 0.82 | ALDH1A1 (0.56) | PTGS1ALDH1A1KDM4ESCN9ACASP3 | |
| SCHEMBL3756968 | 0.81 | ALDH1A1 (0.55) | PTGS1ALDH1A1KDM4ESCN9ACASP3 | |
| SCHEMBL12361502 | 0.77 | ALDH1A1 (0.54) | PTGS1ALDH1A1KDM4ESCN9ACASP3 | |
| SCHEMBL7205942 | 0.77 | PTGS1 (0.58) | PTGS1ALDH1A1KDM4ESCN9ATGFBR1 | |
| SCHEMBL7205947 | 0.77 | PTGS1 (0.58) | PTGS1ALDH1A1KDM4ETGFBR1PTGS2 | |
| SCHEMBL12361513 | 0.75 | PTGS1 (0.47) | PTGS1ALDH1A1KDM4ESCN9ACASP3 | |
| SCHEMBL12361519 | 0.75 | PTGS1 (0.52) | PTGS1ALDH1A1KDM4ESCN9APTGS2 | |
| SCHEMBL3756976 | 0.74 | ALDH1A1 (0.65) | PTGS1ALDH1A1KDM4ETGFBR1PTGS2 | |
| SCHEMBL28957484 | 0.74 | PTGS1 (0.58) | PTGS1ALDH1A1KDM4EPTGS2NR3C2 | |
| SCHEMBL6389180 | 0.73 | PTGS2 (0.53) | PTGS1PTGS2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956260-B1 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-05-01 | — | — | US | disclosed |
| US-9352010-B2 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-14 | — | — | US | disclosed |
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2015-12-03 | — | — | US | disclosed |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | PTGS1 499/4885ALDH1A1 2603/4885KDM4E 1246/4885 |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | HMGB2, HMGB3, HMGB1 | PTGS1 101/4885ALDH1A1 3437/4885KDM4E 4242/4885 |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | PTGS1 499/4885ALDH1A1 2603/4885KDM4E 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.